Our top pick for
MeiraGTx Holdings plc is a biotechnology business based in the US. MeiraGTx shares (MGTX) are listed on the NASDAQ and all prices are listed in US Dollars. MeiraGTx employs 206 staff and has a trailing 12-month revenue of around USD$18.7 million.
|52-week range||USD$8.82 - USD$18.74|
|50-day moving average||USD$15.7844|
|200-day moving average||USD$14.3002|
|Wall St. target price||USD$36.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.622|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$18.7 million|
|Gross profit TTM||USD$13.3 million|
|Return on assets TTM||-11.21%|
|Return on equity TTM||-28.35%|
|Market capitalisation||USD$673.8 million|
TTM: trailing 12 months
There are currently 398,778 MeiraGTx shares held short by investors – that's known as MeiraGTx's "short interest". This figure is 0.7% down from 401,538 last month.
There are a few different ways that this level of interest in shorting MeiraGTx shares can be evaluated.
MeiraGTx's "short interest ratio" (SIR) is the quantity of MeiraGTx shares currently shorted divided by the average quantity of MeiraGTx shares traded daily (recently around 123079.62962963). MeiraGTx's SIR currently stands at 3.24. In other words for every 100,000 MeiraGTx shares traded daily on the market, roughly 3240 shares are currently held short.
However MeiraGTx's short interest can also be evaluated against the total number of MeiraGTx shares, or, against the total number of tradable MeiraGTx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MeiraGTx's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 MeiraGTx shares in existence, roughly 10 shares are currently held short) or 0.0126% of the tradable shares (for every 100,000 tradable MeiraGTx shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MeiraGTx.
Find out more about how you can short MeiraGTx stock.
We're not expecting MeiraGTx to pay a dividend over the next 12 months.
Over the last 12 months, MeiraGTx's shares have ranged in value from as little as $8.82 up to $18.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MeiraGTx's is 1.3337. This would suggest that MeiraGTx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.